Stonegate Updates Coverage on Burcon Nutrascience Corporation (BU) FY26 Q1
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2025
0mins
Should l Buy ?
Source: Yahoo Finance
Commercial Production Achievements: Burcon Nutrascience Corporation successfully launched its Peazazz® C pea protein and FavaPro fava protein, achieving first commercial production within 90 days of commissioning its Galesburg facility, supported by strong market reception.
Financial Developments: The company entered a $6.8 million multi-year production agreement, contributing to a revenue target of $1-3 million for 2025, while Q1 FY26 revenue rose 44% year-over-year to $0.34 million despite startup costs impacting margins.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
